Back

The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials

29 August 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Hua Shen

Beijing Anzhen Hospital, Beijing (China)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor Z. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Doctor E. Bolsteina (Riga, LV)
Abstract Slides
Presentation thumbnail
Professor S. Hong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Doctor X. Liu (CH)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

The Event

Event poster

ESC Congress 2025

29 August 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study
thumbnail
Congress Presentation
Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials
thumbnail
Congress Presentation
Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources